NRAS and neoplasm: No significant difference in DFS was observed between patients with KRAS wild type and mutants (P = 0.727), furthermore subgroups such as codon 12/13 and mutation types (G12D/G12V/G12C/G12S/G13D) did not appear as prognostic factors for DFS, stratified by tumor stage or analyzed together, we also failed to discover significant associations between BRAF/PIK3CA/NRAS mutations and DFS (Fig. 1).